Navigation Links
Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting

0 days.

About Dimebon

Dimebon, the Company's lead product candidate, is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system. Dimebon appears to block a new target that involves mitochondrial pores, which are believed to play a role in the cell death that is associated with neurodegenerative diseases and the aging process. Medivation is currently evaluating Dimebon in clinical trials in both Alzheimer's and Huntington's diseases.

Six-month results from the Phase 2 efficacy study demonstrated that patients treated with Dimebon were significantly improved compared to patients taking placebo on all five efficacy endpoints studied, which assessed cognitive function, memory, ability to perform tasks of daily living, global function and behavior. Dimebon was well tolerated in the study.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to www.medivation.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Liti
'"/>




Page: 1 2 3

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:12/1/2009)..., , ARLINGTON, Va., Dec. 1 /PRNewswir... its newest report, The Market Outlook for Resea...appropriated to the NIH Scientific Research progra...RRA) is being earmarked for lab renovations, Chall...d research that spans multiple public and non-prof...
(Date:12/1/2009)..., , ATLANTA, Dec. 1 /PRNewswire-FirstCal...ogical medical device and cardiovascular tissue pr...guidance for 2010. ,, The Company expects total...$118.0 million and $123.0 million, which includes ...unding received from the Department of Defense in ...
(Date:12/1/2009)..., , CHICAGO, Dec. 1 A...ociety of North America (RSNA), Royal Philips Elec...al Breast Workspace, a set of solutions that provi...ity breast images at one workspot to help drive qu...o breast care, Philips will also highlight new cap...
Breaking Medicine Technology:BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 2BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010 3CryoLife Provides Initial 2010 Financial Guidance 2CryoLife Provides Initial 2010 Financial Guidance 3CryoLife Provides Initial 2010 Financial Guidance 4CryoLife Provides Initial 2010 Financial Guidance 5Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4Suicide Risk With Antidepressants Falls With Age 54272 1Suicide Risk With Antidepressants Falls With Age 54272 2Suicide Risk With Antidepressants Falls With Age 54272 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Imitrex 28R 29 Tablets 54270 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Imitrex 28R 29 Tablets 54270 2HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 1HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 2HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 3HearUSA Makes Hearing Aids and Care Available to AARP Members 54269 4
...announced today at the American Diabetes Associati...ulin detemir [rDNA origin] injection) can,be used ...onse to insulin,glargine over a 24-hour period in ...rces that once-daily Levemir has a similar 24-hour...essor Allen B. King,Diabetes Care Center, Salinas,...
...ific Sessions, SAN FRANCISCO, June 7 Sanofi-aven...inding study for its new,injectable diabetes compo...e American Diabetes Association,s (ADA) 68th Annua...lifornia., The study found that AVE0010 was well ...rol versus placebo in type 2 diabetes patients,ina...
Other Medicine Technology:New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes 2New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes 3New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes 4New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 2New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 3New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study 4
(Date:12/1/2009)..., WASHINGTON, Dec. 1 In...are more likely than those with traditional covera..., to be more engaged in wellness programs, and to ...s matter in holding down costs, according to surve...ee Benefit Research Institute (EBRI). ,, At th...
(Date:12/1/2009)..., PHOENIX, Dec. 1 Abrazo Media R...nd Scoliosis ( http:// www.pedsorthopaedics.com ) ... orthopaedic surgeon Dr. J. Hunt Udall to its prac...ne and orthopaedic surgery after recently completi...n Boston, Massachusetts where he focused on adult ...
(Date:12/1/2009)..., FORT LAUDERDALE, Fla., Dec. 1 O...t enrollment in the randomized clinical trial of t...ombo Stent). ,, A prospective, randomized, mult...ion of an ablu M inal sirolimus coat ED bio- ...at up to 20 sites in Asia, Australia, Europe and S...
(Date:12/1/2009)... 1, 2009) The ADEAGies Foundation will honor The ...Award at the Gies Awards celebration to be held on...ion with the 2010 ADEA Annual Session & Exhibition...n, and Achievement recognize contributions to, and...atives. For a complete listing of Gies Award winne...
(Date:12/1/2009)... patients in California are unable to successfully... at hospitals despite recent state legislation int...a new study. , Posing as low-income uninsured pa...less than one-third of the hospitals they approach...er than those allowed under California law, accord...
Breaking Medicine News(10 mins):Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 2Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 3Health News:New Research From EBRI: Consumer-Driven Health Plan Participants Display Cost-Conscious Behavior, Utilize Wellness Programs 4Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 2Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 3Health News:OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent 4Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2Health News:Hospital price transparancy laws in California fall short, study finds 2
...n as physical disability does, study shows , ...ssion stops stroke victims from returning to work ...alian researchers report. , The study of 210 men a...a recent U.S. study, said researchers at the Georg...
...ion Diagnostics,LLC, the premier provider of compr... medication monitoring, and support services natio...hensive website. The new site, http://www.dominion...omer services and create a centralized location of...
...,(Nasdaq: BLUD ), a global leader in providing au...ansfusion industry, today announced that it expect..., April 1, 2008, after the,close of regular tradin...his conference call, with Dr. Gioacchino De,Chiric...
...sdaq:,CRYO), reported today that its Annual Report...ing concern" qualification. The going-concern,qual...t registered public,accounting firm expressing sub...ional working capital. In its Annual,Report on For...
... under review by U.S. agency and manufacturer Merc...-- The U.S. Food and Drug Administration said Thur...creased risk of mood changes and suicidal behavior..., it posted sales of $4.3 billion, making it Merck...
...cells to their destination in the body , ,...em cell lab" created by U.S. researchers holds pro...applications, as well as in the design of certain ...ll. uses one polymer and one small molecule that i...
Other Medicine News:Health News:Depression After Stroke Can Be Debilitating 2Health News:Dominion Diagnostics Announces Launch of Comprehensive New Company Website 2Health News:Immucor Schedules Third Quarter Earnings Release and Conference Call 2Health News:CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders' Equity 2Health News:CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders' Equity 3Health News:FDA Probing Possible Link Between Asthma Drug and Suicide Risk 2Health News:FDA Probing Possible Link Between Asthma Drug and Suicide Risk 3Health News:Researchers Create Protective Sac for Growing Stem Cells 2
AB-180 iVAD
Safeguard
Icy
PeriVac Pericardiocentesis Kit with 7F pigtail catheter
Medicine Products: